NYSE: DHRDanaher Corp Stock
$215.91+4.41 (+2.09%)
Updated Aug 20, 2026
DHR Price
$215.91
Fair Value Price
N/A
Market Cap
$151.78B
52 Week Low
$160.93
52 Week High
$242.80
P/E
38.21x
P/B
2.89x
P/S
5.51x
PEG
1.74x
Dividend Yield
0.67%
Revenue
$25.11B
Earnings
$4.00B
Gross Margin
58.5%
Operating Margin
20.19%
Profit Margin
15.9%
Debt to Equity
0.76
Operating Cash Flow
$7B
Beta
0.89
Next Earnings
Oct 20, 2026
Ex-Dividend
N/A
Next Dividend
N/A
DHR Overview
Danaher Corporation is a diversified conglomerate that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. Its segments are Life Sciences, Diagnostics, and Environmental & Applied Solutions. Originally organized in 1969 as a Massachusetts real estate investment trust (REIT) and known as DMG until 1984, the company is headquartered in Washington, D.C.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DHR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
DHR
Ranked#13 of 38
Ranked#13 of 38
Be the first to know about important DHR news, forecast changes, insider trades & much more!
DHR News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DHR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DHR ($215.91) is trading above its intrinsic value of $68.82, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DHR is poor value based on its earnings relative to its share price (38.21x), compared to the US market average (18.09x)
P/E vs Market Valuation
DHR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more DHR due diligence checks available for Premium users.
Valuation
DHR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
38.21x
Industry
14.16x
Market
18.09x
DHR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DHR is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
DHR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.89x
Industry
4.46x
DHR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DHR price to earnings growth (PEG)
For valuing profitable companies with growth potential
DHR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
DHR's financial health
Profit margin
Revenue
$6.3B
Net Income
$870.0M
Profit Margin
13.9%
DHR's Earnings (EBIT) of $5.07B... subscribe to Premium to read more.
Interest Coverage Financials
DHR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$92.4B
Liabilities
$39.8B
Debt to equity
0.76
DHR's short-term assets ($13.38B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DHR's long-term liabilities ($31.67B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DHR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DHR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.5B
Investing
-$10.1B
Financing
$7.3B
DHR's operating cash flow ($6.64B)... subscribe to Premium to read more.
Debt Coverage Financials
DHR vs Diagnostic & Research Stocks
Danaher Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.